Chronic Disease Management Market Size, Share, Growth, Trends, and Global Industry Analysis: By Disease Type (Cardiovascular Diseases, Diabetes, Cancer, Asthma, Chronic Obstructive Pulmonary Disorders & Others), By Service Type (Disease Management Programs, Remote Patient Monitoring, Telehealth Services & Others), By End User (Multispecialty Hospitals, Speciality Clinics, Healthcare  Payers & Others), and Region, Forecast 2019-2030.

Chronic Disease Management Market size was valued at US$ 15,903.7 million in 2023 and is projected to reach a value of US$ 39,551.6 million by 2030, at a CAGR of 13.9% from 2024-2030.  Chronic disease management refers to the coordinated care and strategies designed to help individuals effectively manage long-term health conditions such as diabetes, hypertension, heart disease, arthritis, asthma. etc. Chronic disease management involves regular monitoring, medication adherence, lifestyle changes, patient education, and often, multidisciplinary healthcare teams to address the complex needs of patients and the goal is to reduce the severity of symptoms, prevent disease progression, and improve overall health outcomes.

The key growth drivers of market are increasing geriatric population with decreased immunity, rise in musculoskeletal diseases, growing awareness and patient engagement. However, the restraints of market are high costs of chronic disease management solutions, limited access to digital health infrastructure. The key emerging opportunities of market are the increasing adoption of digital health solutions such as telemedicine and remote monitoring, innovations in healthcare technology such as wearable devices and AI-driven analytics. The key trends of market are adoption of disease management apps. 

Key Players  

The leading companies highlighted in the chronic disease management market report include such as Abbott has products like FreeStyle Libre a continuous glucose monitoring system for diabetes management, CardioMEMS HF System a heart failure monitoring device ; Abbvie Inc focuses on immunology and chronic disease therapies, especially in rheumatology and neurology ; Amgen Inc offers products like Repatha for lowering cholesterol, Prolia for osteoporosis treatment ; Astellas Pharma Inc Japanese multinational focused on urology, oncology, and transplantation ; AstraZeneca has products like Symbicort for asthma and COPD, Brilinta for reducing cardiovascular events and other key players are Bausch Health Companies Inc., Bayer Ag, Boehringer Ingelheim International GmBH, Boston Scientific Corp., Bristol-Myers Squibb Co., Dr. Reddy's Laboratories Ltd., Novartis AG, Pfizer Inc. Also, a comprehensive analysis of industry verticals and market participants that provides a clear overview of the competitive landscape in relation to the sectors served by the company’s products and services, market share, service offerings, financial reports, significant developments, market strategy, competitive position, and geographic reach.

Key Takeaways

•    North America is expected to generate the largest share in 2024-2030.
•    The Asia Pacific is expected to expand at highest CAGR from 2024 to 2030.
•    Based on disease type, cardiovascular diseases are expected to be the leading disease type in the market in 2024.
•    Based on service type, the disease management program services holds the highest market share in 2023. 
•    Based on end user, the multispecialty hospitals has captured the highest market share in 2023.  

Facts & Figures 

•    In 2020, Apple expanded its healthcare focus through the Apple Watch and its HealthKit platform, it introduced new features that allow patients with chronic conditions, such as cardiovascular diseases, to monitor heart health, blood oxygen levels, and activity.
•    In 2021, Medtronic expanded its remote patient monitoring capabilities by partnering with GE Healthcare to deliver chronic disease management solutions focusing on managing cardiac diseases and diabetes.
•    In 2024, Pfizer expanded its partnership with BioNTech beyond COVID-19 vaccines to develop mRNA-based therapies targeting chronic conditions such as cancer and cardiovascular diseases. This collaboration focuses on leveraging mRNA technology for therapeutic solutions that can provide better long-term management of chronic diseases.

Key Developments 

• In April 2021, WellSky introduced an advanced home health visit management solution called Care Insights Guidance. This gave a new feature of maintaining quality of treatment with improvements in patient health.   

Chronic Disease Management Market Segmentation

Among all the disease types, the cardiovascular diseases(CVDs) segment is dominant in chronic disease management market, with an estimated 30% share. This is due to the increasing prevalence of CVDs, such as stroke, arrhythmia, and aortic aneurysm. CVDs are also widespread and require ongoing management to prevent serious complications.

By Service Type: In service type, the disease management programs (DMPs) segment is dominant due the growing demand for efficient and cost-effective solutions and they help improve the quality of life for people with chronic diseases. DMPs use the latest medical knowledge to treat chronic diseases, relieve symptoms, and prevent complications which makes it more accessible and efficient. 

By End User: Among all end user segment, the multispecialty hospitals sub segment is dominant in the market as it has all facilities for every specific disease to treat and cure. It also has large accommodation which can treat all patients. As multispecialty hospitals will engage with high specialty doctors and nurses the patients are well treated with more personalized patient care.